

Supplemental Table for:

BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies Jan Schellens et al.

 Table S1. Overview of clinical trials included in meta-analyses on BRAF mutations.

	Study design	Treatment line F	Pietrantonio	Rowland	Therkildser	Yuan	Xu	Wang	Cui
Bokemeyer 2011 (OPUS)	RCT	1 st				2.50.7			х
Bokemeyer 2012 (OPUS + CRYSTAL)	RCT	1 st	х	x	x	x		x	
Benvenuti 2007	Retrospective	1 st and ≥2 nd				x	х		
Cappuzzo 2008	Retrospective	≥2 nd				х	х		
De Roock 2010	Retrospective	≥2 nd			х	х	х	х	
Di Nicolantonio 2008	Retrospective	≥2 nd				Х	х		
Douillard 2013 (PRIME)	RCT	1 st	x	х	x				
Fornaro 2011	Retrospective	≥2 nd				x	х		
Freeman 2008	Retrospective	1 st and ≥2 nd				х	х		
Gao 2011	RCT	n.r.			х				
Garcia 2011	RCT	≥2 nd			x		х		
Inno 2011	RCT	n.r.			х				
Karapetis 2014	RCT	Refractory	х	Х					
Laurent-Puig 2009	Retrospective	≥2 nd				х	х		
Loupakis 2009	RCT	Irinotecan- refractory			х	х	х	x	
Modest 2012 (AIO-KRK0104)	RCT	1 st			х	х	х	x	х
Molinari 2009	RCT	Refractory			x	х	х		
Montagut 2010	Retrospective	1 st and ≥2 nd					х		
Moroni 2005	Retrospective	1 st and ≥2 nd				x	х		
Park 2011	RCT	≥2 nd			x	х		х	
Peeters 2013	RCT	Refractory	x	x	×				
Peeters 2014	RCT	2 nd	х	х					



Supplemental Table for:

BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies Jan Schellens et al.

Perrone 2009	RCT	Irinotecan- refractory			x	х	х		
Saridaki 2011	RCT	$\geq 2^{nd}$			X	х	Х	х	
Sartore Bianchi 2009	Retrospective	1 st and ≥2 nd				x	x		
Seymour 2013 (PICCOLO)	RCT	≥2 nd	x	х					
Smith 2013	RCT	1 st	x	х					
Soeda 2013	RCT	≥3 rd			Х				
Spindler 2011	Prospective	3 rd				х			
Stintzing 2014 (FIRE-3)	RCT	1 st	х						
Tol 2010	RCT	1 st			х	х	х		
Tural 2013	RCT	Refractory			х				
Tveit 2011 (Nordic VII)	RCT	1 st	x			х	x		x
Ulivi 2012	Prospective	≥2 nd			Х			х	
Van Cutsem 2011 (CRYSTAL)	RCT	1 st				х	x		x
Wong 2011	Prospective	1 st				х			

RCT = randomized clinical trial; n.r. = not reported